10.6084/m9.figshare.11497527.v1
Brianna Craver
Brianna
Craver
Thanh Nguyen
Thanh
Nguyen
Jenny Nguyen
Jenny
Nguyen
Hellen Nguyen
Hellen
Nguyen
Christy Huynh
Christy
Huynh
Sarah Morse
Sarah
Morse
Angela Fleischman
Angela
Fleischman
MOESM3 of The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells
Springer Nature
2020
Myeloproliferative neoplasm
SMAC mimetic
TNFα
2020-01-03 04:55:33
Journal contribution
https://springernature.figshare.com/articles/journal_contribution/MOESM3_of_The_SMAC_mimetic_LCL-161_selectively_targets_JAK2V617F_mutant_cells/11497527
Additional file 3: Figure S3. Calreticulin-mutant cells are not hypersensitive to LCL-161. (A, B) Resazurin-based cell viability assay showing L929 cells transduced with the Calreticulin (CALR) mutations representing empty vector (EV), wild-type CALR (CALRWT), deletion (CALRDEL) or insertion (CALRINS) (A) containing thrombopoietin receptor (MPL) and (B) without MPL treated with increasing concentrations of LCL-161 for 48 h. **P < 0.01, ***P < 0.001 2way ANOVA. (C) Western blot for cIAP1/2, XIAP, and β-Actin as a loading control in CALRWT, CALRDEL, CALRINS, or empty vector (VEH) cells in the presence or absence of MPL. (D) Myeloid colony formation using MNCs from normal controls (n = 5), CALR-mutated patients (n = 5), and JAK2V617F patients (n = 5). Cells were plated in methylcellulose with varying LCL-161 concentrations. Colonies were counted from each plate and normalized to 0 µM LCL-161. Error bar represent mean values ± SEM.